Published on
May 4, 2023
- 20:05 GMT
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programs in hepatitis B and D, and influenza – – Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company through next phase of growth – – $2.3 billion in cash, …
Distribution channels:
Business & Economy, Technology
...
